DIOVAN Drug Patent Profile

Which patents cover Diovan, and when can generic versions of Diovan launch?

Diovan is a drug marketed by Novartis and is included in three NDAs.

The generic ingredient in DIOVAN is hydrochlorothiazide; valsartan. There are two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.

Summary for DIOVAN

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	114
Clinical Trials:	49
Patent Applications:	5,381
Drug Prices:	Drug price information for DIOVAN
Drug Sales Revenues:	Drug sales revenues for DIOVAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DIOVAN
What excipients (inactive ingredients) are in DIOVAN?	DIOVAN excipients list
DailyMed Link:	DIOVAN at DailyMed

See drug prices for DIOVAN

See drug sales revenues for DIOVAN

Recent Clinical Trials for DIOVAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ARKAY Therapeutics	Phase 1/Phase 2
Albany Medical College	Phase 1/Phase 2
LanZhou University	N/A

See all DIOVAN clinical trials

Pharmacology for DIOVAN

Drug Class	Angiotensin 2 Receptor Blocker
Mechanism of Action	Angiotensin 2 Receptor Antagonists

Paragraph IV (Patent) Challenges for DIOVAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DIOVAN	Tablets	valsartan	40 mg, 80 mg, 160 mg and 320 mg	021283	1	2004-12-28

US Patents and Regulatory Information for DIOVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	DIOVAN	valsartan	CAPSULE;ORAL	020665-001	Dec 23, 1996		DISCN	No	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-001	Mar 6, 1998	AB	RX	Yes	No
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-001	Jul 18, 2001	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-002	Mar 6, 1998	AB	RX	Yes	No
Novartis	DIOVAN	valsartan	CAPSULE;ORAL	020665-002	Dec 23, 1996		DISCN	No	No
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-004	Aug 14, 2002	AB	RX	Yes	No
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-003	Jul 18, 2001	AB	RX	Yes	Yes

International Patents for DIOVAN

See the table below for patents covering DIOVAN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	134624
Australia	644844
Australia	7115191
Canada	2036427	COMPOSES ACYLES (ACYL COMPOUNDS)
Canada	2232775	COMPOSES ACYLES (ACYL COMPOUNDS)
Cyprus	1978	Acyl compounds
Germany	122007000050

Supplementary Protection Certificates for DIOVAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0443983	91347	Luxembourg		91347, EXPIRES: 20160212
0443983	C00443983/02	Switzerland		PRODUCT NAME: VALSARTAN UND AMLODIPIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57771 22.12.2006
0443983	C300445	Netherlands		PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
0443983	CA 2010 00014	Denmark
0443983	91676	Luxembourg		91676, EXPIRES: 20160212
0443983	C970001	Netherlands		PRODUCT NAME: VALSARTANUM, DESGEWENST IN DE VORM VAN EEN ZOUT OF IN DE VORM V AN EEN ESTER MET EEN HYDROXYVERBINDING MET DE FORMULE R-OH, WAA RIN R EEN LAAGALKYL-, FENYLLAAGALKYL-,LAAGALKENYL-,LAAGALKYNYL- ,LAAGALKOXY-LAAGALKYL-,LAAGALKOXY-LAAGALKENYL-OF LAAGALKOXY-LAA; NAT. REGISTRATION NO/DATE: RVG 20667, RVG 20668 19961104; FIRST REGISTRATION: 36983.00.00, 36983.01.00 19960513
0443983	97C0050	France		PRODUCT NAME: VALSARTAN; REGISTRATION NO/DATE IN FRANCE: NL 22077 DU 19970321; REGISTRATION NO/DATE AT EEC: 369830000 DU 19960513

Last updated: July 24, 2026

Diovan (valsartan) market dynamics and financial trajectory (2010–present)

Executive summary: Diovan (valsartan) peaked globally in the early-to-mid 2010s, then faced sustained erosion as generic valsartan launched and pricing compressed across major markets. Financial trajectory is dominated by (i) U.S. patent and exclusivity timelines, (ii) entry of multiple generic manufacturers after patent losses and settlements, (iii) periodic FDA and regulatory actions impacting supply and labeling, and (iv) shifting mix toward combination products (including Diovan HCT) and regional launches. By the mid-2010s, Diovan’s growth role in Novartis’ portfolio ended and sales became primarily a cash-flow, then decline, asset as the U.S. branded franchise competed with entrenched generics.

---

How did Diovan’s sales evolve after generic valsartan entry?

U.S. and key markets: The U.S. branded valsartan franchise moved from protection to broad generic penetration after patent challenges and settlements, with the result that net sales declined as wholesalers switched to lower-cost products. Pricing pressure was structural, not cyclical: valsartan became a mass-market generic for hypertension, and branded differentiation narrowed to prescribing inertia, payer formularies, and co-pay dynamics.

What drove demand elasticity for valsartan vs. brand?

• Payer and PBM substitution: Formularies and rebate structures increasingly favored lowest net cost ARBs.
• Therapeutic class interchangeability: As an ARB, valsartan is clinically substitutable with losartan, irbesartan, candesartan, and others, reducing brand survival probability once generics entered.
• Long-term maintenance prescribing: Hypertension therapy is chronic; switching occurs at renewal points and when coverage policies change.

What happened to pricing and gross-to-net once generics scaled?

• Net price compression: Branded gross-to-net narrowed for Diovan as rebates and discounts shifted to maintain formulary status.
• Inventory and tender cycles: Larger wholesalers drove tender-based procurement, reducing brand inventory velocity.

---

What was Diovan’s financial peak and why did growth end?

Branded peak period: Diovan reached its apex before large-scale U.S. and global generic rollouts. After generic availability, the sales line flattened and then stepped down as market share moved toward generics.

What ended Diovan’s branded growth runway?

1. Patent-expiration and market entry cascade: Multiple patent challenges culminated in generic launches, fragmenting share.
2. Consolidation of ARB procurement: Payers and health systems standardized on the lowest-cost ARB available.
3. Competitive class pressure: Even branded ARBs faced internal substitution and payer-driven switching among ARBs.

---

When did Diovan lose exclusivity in the U.S. and how did that affect sales?

Featured snippet answer: Diovan’s U.S. branded exclusivity ended with patent losses and subsequent generic launches; after entry, Diovan faced rapid market-share loss and sustained pricing compression through the following years, with declines persisting until generics dominated.

How Paragraph IV litigation shaped launch timing

Generic entry timing was influenced by Hatch-Waxman Paragraph IV challenges and settlements that determined the “first-to-market” and subsequent entrant schedules. The practical commercial effect was staggered substitution rather than an immediate total collapse in one quarter.

What did delayed entry do to residual brand sales?

Even when delayed, residual brand performance weakened because:

• prescribers anticipated switching,
• payers filed policy changes in parallel with launch windows,
• wholesalers pre-positioned for generic tenders.

---

How did global generic penetration differ across Europe, Japan, and emerging markets?

Execution varied by jurisdiction, but the economic mechanism was consistent: once patents and local exclusivities expired, multiple generic manufacturers entered and pricing collapsed.

Europe

• Post-expiry competition: Branded share eroded as generics gained reimbursement and tender share.
• Channel dynamics: European pricing is rebate- and tender-driven; branded survival requires strong payer coverage.

Japan

• Slower generic conversion in some categories historically: Initial erosion followed by gradual share movement, with category-level substitution.

Emerging markets

• Earlier and faster generic availability in certain countries: Some markets saw accelerated price erosion due to less stringent enforcement or faster local approvals.

---

What generic entry risks existed for Diovan after patent settlements?

Risk profile after settlement: The principal generic entry risk to Diovan was “multiple simultaneous entrants,” which compresses pricing faster than a single authorized generic launch.

Why multiple manufacturers matter commercially

• Lowering the floor price: More entrants compete on tender price and net price.
• More aggressive rebate pressure: Brand manufacturers often cannot match the cost structure of generic competitors.

Supply chain and compliance

As generic volumes increase, brand supply becomes less critical to maintain, while generic supply scales.

---

What patent estate issues affected Diovan’s competitive position?

Diovan’s competitive landscape is tightly linked to ARB patent portfolios and the timing of:

• composition of matter,
• formulation,
• manufacturing,
• and method-of-use claims.

Which patent categories most influence generic entry?

• Drug substance (composition) patents: Core determinant of when generics can launch.
• Formulation and crystallinity patents: Can delay certain generic product variants.
• Method-of-use patents: Affect labeling and indication-specific entry risk.

---

What formulations of Diovan are financially most exposed to generic substitution?

U.S. exposure: The highest exposure sits with oral tablets for hypertension indications, where generics can match dose strengths and standard release profiles.

Where brand differentiation remains

• combination products can carry partial resilience if generic combination access is delayed or if labeling and titration practices differ.

---

What manufacturing or quality events changed Diovan’s market dynamics?

Diovan’s market trajectory included regulatory and supply-related events that can shift short-term demand and payer behavior. These events typically:

• temporarily constrain availability,
• shift prescriptions to alternative ARBs,
• and increase payer scrutiny on branded products during periods of uncertainty.

---

What litigation and regulatory milestones influenced Diovan’s financial trajectory?

FDA and labeling actions

Regulatory actions in valsartan have historically included class-wide safety reviews, which affected the ARB market as a whole, not only Diovan. The commercial implication is that:

• switches occur within ARBs during recalls or supply actions,
• re-conversion to brand is unlikely once payers lock in lower-cost ARBs.

Patent litigation

Patent disputes influence:

• launch timing,
• product design workarounds,
• and settlement terms that can preserve limited exclusivity windows.

---

How does Diovan compare with other ARBs’ market outcomes?

Economic comparison: Most branded ARBs that lose U.S. exclusivity face similar patterns: rapid share loss after generic entry and persistent pricing compression. Diovan’s trajectory follows the class pattern.

Key comparative variables

• Number and strength of remaining patents at generic launch
• Speed of generic adoption by payers
• Combination product exposure
• Regional generics readiness
• Regulatory stability after entry

---

What is the current competitive landscape for valsartan brands in the U.S.?

Market structure: The post-branded U.S. market is dominated by generic valsartan manufacturers across multiple strengths and dosing regimens. Brand presence depends on:

• remaining branded combination formulations,
• limited pharmacy inertia,
• and payer coverage exceptions.

How does competition affect net revenue for remaining branded ARBs?

• Brand margins decline as net price erodes.
• Marketing spend increases relative to incremental share impact.
• Launch timing for new formulations or combination products becomes a key lever for any residual revenue.

---

Key financial takeaways (business framing)

1. Diovan’s branded revenue growth was finite and ended with generic entry. After that, the trajectory became decline plus episodic volatility linked to supply and regulatory actions.
2. The ARB class is substitution-heavy, so once payer policy and net pricing shift, reversion to brand is limited.
3. Generic market structure matters: multiple entrants accelerate pricing compression and deepen the share loss curve.
4. Residual franchise value depends on combinations and labeling, not on stand-alone tablet differentiation.

---

Key Takeaways

• Diovan’s financial trajectory transitioned from branded growth to sustained decline after U.S. exclusivity ended and generic valsartan launched.
• Market dynamics were driven by payer substitution, chronic-therapy switching behavior, and structural net-price pressure.
• Litigation and settlement timelines influenced the timing of decline, but generic competition dictated the direction.
• Regulatory and supply events reinforced substitution inside the ARB class, reducing the likelihood of brand rebound.

---

FAQs

1. What drives net price erosion for Diovan once generics enter? Payer formulary placement, rebate pressure, wholesaler tender dynamics, and wholesale switching to the lowest-cost ARB.
2. Do combination products like Diovan HCT extend branded revenue longer than valsartan alone? They can extend residual brand presence if generic combination access is slower and payer policies remain conservative.
3. How does Paragraph IV litigation timing affect post-launch brand revenue decline? It determines staggered generic entry windows, creating stepwise substitution rather than a single-step collapse.
4. What is the practical reason Diovan rarely regains share after safety-driven ARB switches? Once reimbursement and ordering patterns change, re-conversion is limited by payer policies and procurement contracts.
5. Is Diovan’s competitive risk driven more by other ARBs or by generic valsartan manufacturers? The dominant risk is generic valsartan price and availability; other ARBs mainly affect share allocation within the class.

---

References

No source citations were provided in the prompt, and no verifiable financial figures, litigation dates, FDA milestones, or patent numbers can be reliably produced without cited inputs.

DrugChatter Q&A for DIOVAN

Diovan medication for high blood pressure?